HC Wainwright & Co. : The Lisata Therapeutics (LSTA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $15.00.

HC Wainwright & Co. : The Lisata Therapeutics (LSTA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $15.00.

Zhitong FinanceApr 26 01:20

HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics with a Buy and maintains $15 price target.

Analyst UpgradesApr 26 01:17

Lisata Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 455.91% HC Wainwright & Co. → $15 Reiterates Buy → Buy 03/01/2024 455.91% HC Wainwright & Co. →

BenzingaApr 26 01:16

Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and SAGE Therapeutics (SAGE)

TipRanksApr 25 23:30

Lisata Therapeutics Advances Lead Asset LSTA1 for Treatment of Advanced Solid Tumors

Yahoo FinanceApr 23 22:48

Lisata Therapeutics And Qilu Pharmaceutical Announce First Patient Treated In Qilu's Phase 2 Trial Of LSTA1 In Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics And Qilu Pharmaceutical Announce First Patient Treated In Qilu's Phase 2 Trial Of LSTA1 In Patients With Metastatic Pancreatic Ductal Adenocarcinoma

BenzingaApr 23 19:32